Perpetual punishment? Study looks at how past criminal convictions affect housing, work chances
Updated 6:31 AM;
Today 6:31 AM
A new study showed disproportionate levels of convictions for Black and Latinx people in New York City. (Cory Morse | MLive.com) Cory Morse
Facebook Share
STATEN ISLAND, N.Y. New research published by the Data Collaborative for Justice (DCJ) at John Jay College found substantial racial disparities in criminal convictions over the past four decades a finding that analysts say sheds light on the need for further conversations surrounding criminal justice reform.
While the study acknowledges that steps have been made to reduce the negative impact of the criminal justice system by shrinking the effect of disproportionate policing on Black and Latino communities, the researchers said that less attention has been paid to addressing how decades of higher enforcement rates lead to criminal records that can present hurdles for people attempting to get a jo
From Autos To Agriculture, These 30 Under 30 Asia Entrepreneurs Are Disrupting Their Industries
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
People deserve clean slates: Criminal records impede post-COVID economic recovery in Black and Brown communities
nydailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nydailynews.com Daily Mail and Mail on Sunday newspapers.
Posted on 802
Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.
The international investment syndicate is led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by SV Health Investors who led the Seed round in 2019.
The proceeds will be used to advance Alchemab’s unique target-agnostic drug discovery platform. The approach interrogates the entire antibody repertoires of individuals from well-defined groups who show unexpected resistance to disease despite genetic disposition or other risk factors predicative of a poor prognosis. Using insights gained, Alchemab can identify naturally pro